HIF banner cropped

Advisory Board

Kenneth J. Arrow

arrowKenneth J. Arrow is Professor Emeritus in the Department of Economics at Stanford University. Joint winner of the Nobel Memorial Prize in Economics with John Hicks in 1972, he is the youngest person to have received this award to date, at age 51. His most significant works are his contributions to social choice theory, notably “Arrow’s impossibility theorem,” and his work on general equilibrium analysis. He has also provided foundational work in many other areas of economics, including endogenous growth theory and the economics of information. For more than fifty years, Arrow has been one of the most influential of all practicing economists.


Noam Chomsky

chomskyAvram Noam Chomsky is an Institute Professor and Professor Emeritus in the Department of Linguistics & Philosophy at MIT, where he has worked for over 50 years. Chomsky has been described as the “father of modern linguistics” and a major figure of analytic philosophy. His work has influenced fields such as computer science, mathematics, and psychology. According to the Arts and Humanities Citation Index in 1992, Chomsky was cited as a source more often than any other living scholar from 1980 to 1992.  He is also the eighth most cited source of all time, and is considered the “most cited living author.” Chomsky is the author of over 100 books.


John J. DeGioia

DeGioiaJohn J. “Jack” DeGioia has been the President of Georgetown University since 2001. He has a strong interest in ethics and global development, and hosted the US launch of the Health Impact Fund proposal in December 2008 at Georgetown. He is an Executive Member of the Council on Competitiveness, a member of the Council on Foreign Relations, and a member of the U.S. National Commission for UNESCO. He was named a Washingtonian of the Year by The Washingtonian magazine in 2008.


Ruth Faden

fadenRuth Faden, a leading bioethicist, holds several scholarly appointments. She is the Philip Franklin Wagley Professor of Biomedical Ethics, Johns Hopkins University; Professor in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health; Professor in the Department of Medicine, Johns Hopkins School of Medicine; Senior Research Scholar at the Kennedy Institute of Ethics, Georgetown University. She is also Director of the Johns Hopkins Berman Institute of Bioethics. Professor Faden’s books include Social Justice: The Moral Foundations of Public Health and Health Policy(with Madison Powers) and A History and Theory of Informed Consent (with Tom L. Beauchamp). She was appointed by President Clinton as chair of the President’s Advisory Committee on Human Radiation Experiments. She holds an M.P.H. and Ph.D. from the Program in Attitudes and Behavior from the University of California, Berkeley.


Paul Farmer

FarmerDr. Paul Farmer is an anthropologist and physician who specializes in infectious diseases. He is a co-founder, along with World Bank President Jim Yong Kim, of Partners in Health, an international nonprofit that provides medical and advocacy services for the poor. He is the chair of the Department of Global Health and Social Medicine at Harvard Medical School and the Chief of the Division of Global Health Equity at Brigham and Women’s Hospital in Boston. He has practiced clinical medicine for many years, including in Haiti, where he was medical director of L’Hôpital Bon Sauveur. He is currently the UN Deputy Special Envoy to Haiti. He has received numerous awards, among them a MacArthur Fellowship and the Hilton Humanitarian Award (for Partners in Health).

Paul Martin

murrayThe Right Honourable Paul Martin was the twenty-first Prime Minister of Canada from 2003 to 2006. He was also Canada’s Minister of Finance during the period 1993 to 2002, during which time he erased Canada’s forty-two billion dollar deficit and recorded five consecutive budget surpluses. He also strengthened the regulations governing Canada’s financial institutions, with the result that Canada is now viewed as an international model for sound financial regulation. In September 1999, Mr. Martin was named the inaugural chair of the Finance Ministers’ G-20. As Prime Minister, Mr. Martin successfully passed a bill implementing Canada’s Access to Medicines Regime.

Currently, Mr. Martin is the co-chair, with Nobel Peace Prize laureate Wangari Maathai, of a two hundred million dollar British-Norwegian poverty alleviation and sustainable development fund for the ten-nation Congo Basin Forest. He also sits on the advisory council of the Coalition for Dialogue on Africa, an initiative that examines critical issues facing the continent. It is sponsored by the African Union, the UN Economic Commission for Africa and the African Development Bank. He is also a member of the International Monetary Fund’s Western Hemisphere Regional Advisory Group.

Christopher Murray

murrayChristopher Murray is the Institute Director of the Institute for Health Metrics and Evaluation (IHME) and Professor of Global Health at the University of Washington School of Medicine. A physician and health economist, his work has led to the development of a range of new methods and empirical studies to strengthen the basis for population health measurement, measure the performance of public health and medical care systems, and assess the cost-effectiveness of health technologies.

Murray’s early work focused on tuberculosis control and the development with Dr. Alan Lopez of the Global Burden of Disease methods and applications. In this work, they developed a new metric to compare death and disability from various diseases and the contribution of risk factors to the overall burden of disease in developing and developed countries. This pioneering effort has been hailed as a major landmark in public health and an important foundation for policy formulation and priority setting.

Murray served as the Executive Director of the Evidence and Information for Policy Cluster at the World Health Organization from 1998 to 2003. From 2003 until 2007, he was the Director of the Harvard University Initiative for Global Health and the Harvard Center for Population and Development Studies, as well as the Richard Saltonstall Professor of Public Policy at the Harvard School of Public Health.


Sir Gustav Nossal

nossalSir Gus Nossal is a world-renowned Australian research biologist. His classic work confirming Burnet’s theory of antibody formation was a watershed in understanding the immune system. He has helped build the foundations of modern immunology as Director of The Walter and Eliza Hall Institute of Medical Research (1965-96). Nossal has worked in the improvement of global health through his long-term involvement with the WHO, most recently as Chairman of the Global Programme for Vaccines and Immunization; as Chairman of the Advisory Committee of the Global Foundation; and as Chairman of the Strategic Advisory Council of the Bill and Melinda Gates Children’s Vaccine Program (1998-2003), among others. Noted appointments in Australia include Deputy Chairman of the Council for Aboriginal Reconciliation (1998-2000); President of the Australian Academy of Science (1994-1998); and Chairman of the Victorian Health Promotion Foundation (1987-1996).


Onora O’Neill

oneillOnora O’Neill is a member of the UK House of Lords. She is a professor of philosophy at the University of Cambridge, President of the British Academy and chairs the Nuffield Foundation. Until October 2006, she was the Principal of Newnham College, Cambridge. She has been a member of the Animal Procedures Committee (1990 to 1994), chair of Nuffield Council on Bioethics (1996 to 1998), and a member and then acting chair of the Human Genetics Advisory Commission (1996 to 1999). She is presently chair of the Nuffield Foundation (since 1997), a trustee of Sense About Science (since 2002), a trustee of the Ditchley Foundation, and a trustee of the Gates Cambridge Trust.

She was made a Life peer as Baroness O’Neill of Bengarve, of The Braid in the County of Antrim in 1999, and in 2007 was elected an honorary FRS. She is also a Foreign Hon. Member of the American Academy of Arts and Sciences (1993) and the Austrian Academy of Sciences (2002), a Foreign Member of the American Philosophical Society (2003), and Hon. Member Royal Irish Academy (2003), a Foreign Member of the Leopoldina (2004) and the Norwegian Academy of Sciences (2006) and a Fellow of the Academy of Medical Sciences.


James Orbinski

orbinskiJames Orbinski is Associate Professor of Medicine and Political Science at the University of Toronto and a research scientist and clinician at St. Michael‘s Hospital at the University of Toronto. He has worked in the field extensively for Médecins Sans Frontières/Doctors Without Borders (MSF), including as Head of Mission in Kigali during the Rwandan genocide of 1994. Orbinski was elected MSF’s international president from 1998 to 2001. He launched its Access to Essential Medicines Campaign in 1999, and in that same year accepted the Nobel Peace Prize awarded to MSF for its pioneering approach to medical humanitarianism, and most especially for its approach to witnessing.

From 2001 to 2004 Orbinski co-chaired MSF’ s Neglected Diseases Working Group, which created and launched the Drugs for Neglected Diseases Initiative (DNDi). The DNDi is a global not-for-profit drug development organization that develops medicines and other health technologies for diseases largely neglected by profit driven research and development companies.

Orbinski is also a founder and Board Chair of Dignitas International, a hybrid academic nongovernmental organization launched to research community-based care, prevention and treatment for people living with HIV in the developing world.


Sir Michael Rawlins

rawlinsSir Michael Rawlins has been chairman of the National Institute of Health & Clinical Excellence (NICE) since its formation in 1999. He is also chairman of the Advisory Council on the Misuse of Drugs (since 1998). He is an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne.

He was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006. At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He was vice-chairman (1987-1992) and chairman (1993-1998) of the Committee on Safety of Medicines.


Karin Roth

rothKarin Roth has been a member of the German Parliament since 2002, representing the Esslingen constituency. From November 2005 to October 2009, she was also Parliamentary State Secretary at the Federal Ministry of Transport, Building and Urban Affairs.  Since November 2009, she has been a member of the Committee for Economic Cooperation and Development and, since April 2010, speaker of the SPD-faction in the Subcommittee on Health in Developing Countries.


Amartya Sen

senAmartya Sen is Lamont University Professor, and Professor of Economics and Philosophy at Harvard University and was until recently the Master of Trinity College, Cambridge. He was formerly Honorary President of OXFAM and is now its Honorary Advisor.

Amartya Sen’s books include Poverty and Famines, Development as Freedom, and Identity and Violence: The Illusion of Destiny among others. His research has ranged over a number of fields in economics, philosophy, and decision theory, including social choice theory, welfare economics, theory of measurement, development economics, public health, gender studies, moral and political philosophy, and the economics of peace and war.

Sen has been awarded numerous awards and honorary degrees, including the Nobel Prize in Economics.


Peter Singer

singerPeter Singer is Ira W. DeCamp Professor of Bioethics in the University Center for Human Values at Princeton University. He first became well-known internationally after the publication of Animal Liberation. His other books include: Practical Ethics; The Expanding Circle; How Are We to Live?, Rethinking Life and Death, One World, Pushing Time Away, The President of Good and Evil, and The Ethics of What We Eat(with Jim Mason). He co-founded The Great Ape Project with Paola Cavalieri, and is currently president of Animal Rights International. In 2005 Time named him one of the world’s 100 most influential people.


Judith Whitworth

whitworthJudith Whitworth is an Emeritus Professor of The Australian National University
and an Honorary Professorial Fellow at the George Institute for International Health in Sydney. She is Chair of the WHO Global Advisory Committee on Health Research (2004-20011) and co-chairs the NSW Health Care Advisory Council.

She graduated MBBS from the University of Melbourne in 1967, MD in 1974, PhD in 1978 and DSc in 1992.  She has honorary degrees from The University of Sydney , the University of New South Wales ,  the University of Glasgow, and Charles Darwin University.


Heidemarie Wieczorek-Zeul

wilderHeidemarie Wieczorek-Zeul is Member of the German Bundestag for Wiesbaden and a member of the Social Democratic Party. From 1998 to 2009, she was Federal Minister for Economic Cooperation and Development. Prior to her election to the Bundestag in 1987, She was a Member of the European Parliament from 1979 to 1987, where she served on the Foreign Trade Committee. Wieczorek-Zeul is a teacher by profession.


Richard Wilder

wilderRichard Wilder is Associate General Counsel of the Bill & Melinda Gates Foundation. Before returning to the private practice of law, Wilder was Director of the Global Intellectual Property Issues Division in the World Intellectual Property Organization (WIPO). There he was responsible for programs dealing with diverse issues, including biotechnology, genetic resources, health care, traditional knowledge, folklore and human rights. Wilder also served in the U.S. Patent and Trademark, Office of Legislative and International Affairs, where he represented the U.S. Government in international negotiations on intellectual property issues.

Before his public service, Wilder practiced intellectual property law in corporate and law firm settings. There he advised clients in all areas of intellectual property, sought protection ( including drafting and filing patent and trademark applications), conducted licensing negotiations, and handled dispute resolution involving intellectual property. In the area of dispute resolution, he handled litigated matters both in U.S. Federal Courts and before the U.S. International Trade Commission.


Dr. Robert C. Gallo

wilderSince 1996, Dr. Robert C. Gallo has been Director of the Institute of Human Virology at the University of Maryland School of Medicine. Previously (for 30 years) he was at the National Cancer Institute (NCI) in Bethesda, MD. While at NCI, he and his co-workers discovered interleukin-2 (Il-2) in 1976. Il-2 was one of the first cytokines (“messenger” molecules that allow cells to communicate and alter one another’s function) and proved to be a major tool not only for immunology but also for the discovery of all human retroviruses. Gallo and his colleagues then opened and pioneered the field of human retrovirology with the discovery of the first human retrovirus (HTLV-1) and along with Japanese investigators showed it was a cause of a particular form of human leukemia. A year later he and his group discovered the second known human retrovirus (HTLV-2). Dr. Gallo and his colleagues also independently discovered HIV, and provided the first results to show that HIV was the cause of AIDS. They also developed the life saving HIV blood test. In 1986 he and his co-workers discovered human herpes virus-6 (HHV-6), the first new herpes virus found in more than 25 years and the cause of Roseola. In 1995 he and his colleagues discovered the first endogenous inhibitors of HIV, namely some of the beta chemokines. This discovery helped in the later discovery of the HIV co-receptor, CCR5, and opened up entire new approaches to treatment of HIV disease.

Dr. Gallo has been awarded 30 honorary doctorates, is a member of the U.S. National Academy of Sciences and Institute of Medicine, and a member of the National Inventors Hall of Fame. He is also the recipient of numerous scientific honors and awards. Dr. Gallo was the most cited scientist in the world 1980-1990, according to the Institute for Scientific Information, and he was ranked third in the world for scientific impact for the period 1983-2002. He has published close to 1,300 papers.


Scientific Advisory Committee

Mary Moran

moranDr. Moran has over 20 years’ experience in health policy and practice, including 10 years specialising in neglected disease policy. She has conducted projects for a wide range of public and multilateral health organisations with a focus on policy solutions for emerging issues related to neglected disease R&D. In 2004, Mary founded the research group that became Policy Cures at the London School of Economics & Political Science, later transferring it to the George Institute for Global Health in Sydney.

Prior to forming the group, she worked for over a decade in Emergency Medicine; was a diplomat and policy analyst with the Australian Department of Foreign Affairs & Trade; Director of Medecins Sans Frontieres Access to Essential Medicines Campaign in Australia; and a Europe-based policy advocate with MSF on issues relating to access to medicines for neglected patients. Mary is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine, and an expert adviser to the World Health Organisation, European Commission, European and Developing Countries Clinical Trials Partnership, Global Alliance for Vaccines and Immunisation (GAVI), OECD and the Wellcome Trust.


Carl F. Nathan


Dr. Nathan, the R. A. Rees Pritchett Professor of Microbiology and Chairman of the Department of Microbiology and Immunology at the Joan and Sanford I. Weill Medical College of Cornell University. He served as Acting Dean of Weill Medical College, Senior Associate Dean for Research, Director of the Tri-Institutional MD-PhD Program, and Co-Chairman of the Department of Cell Biology and Genetics Program at Weill Graduate School of Medical Sciences. He was also the Stanton Griffis Distinguished Professor of Medicine in the Department of Medicine at Weill Medical College.

Dr. Nathan is the author or co-author of more than 150 scientific articles and more than 60 monographs, book chapters, and reviews. He has served as an editor of the Journal of Experimental Medicine since 1988, and also has editorial responsibilities for the Journal of Clinical Investigation and the journal Molecular Medicine. He was recently honored with election to the National Academy of Sciences, Institute of Medicine.

Dr. Nathan received his Bachelor of Arts degree summa cum laude from Harvard College in 1967 and graduated magna cum laude from Harvard Medical School in 1972 with a concentration in immunology. He completed his post-graduate training at Massachusetts General Hospital in 1974 and joined the faculty of The Rockefeller University in 1977.


Mark V. Pauly

paulyMark V. Pauly is Bendheim Professor in the Department of Health Care Management, Professor of Health Care Management, Insurance and Risk Management, and Business and Public Policy at The Wharton School, Co-Director of the Roy and Diana Vagelos Life Sciences and Management Program, and Professor of Economics in the School of Arts and Sciences at the University of Pennsylvania. A former commissioner on the Physician Payment Review Commission, Dr. Pauly has served on the advisory committee to the Agency for Health Care Research and Quality, and on the Medicare Technical Advisory Panel. He currently serves on the National Advisory Council for the National Institutes of Health National Center for Research Resources, the National Academy of Sciences’ Committee to Study the Veterinary Workforce, and the NAS Committee on the Biomedical Workforce. He has been a consultant to the Congressional Budget Office, the Office of the Secretary of the U.S. Department of Health and Human Services (which supported some of his work on individual health insurance), and health trade associations. Dr. Pauly is a co-editor-in-chief of the International Journal of Health Care Finance and Economics and an associate editor of the Journal of Risk and Uncertainty.


Dorairaj Prabhakaran


Dorairaj Prabhakaran is the Executive Director of the Centre for Chronic Disease Control (CCDC). He has worked to establish CCDC as a leading center for research in non-communicable diseases with a strong emphasis on fundamental, translational and clinical research involving cardiovascular diseases, diabetes and cancer. He is a cardiologist and epidemiologist by training. Until September 2007, he was Additional Professor of Cardiology at the All India Institute of Medical Sciences (AIIMS), New Delhi. He received his MD and DM (Cardiology) degrees from AIIMS. He has done an MSc in Health Research Methodology from McMaster University, Canada and has a career commitment to preventive cardiology.  He has been elected as a Fellow of the Royal College of Physicians ( London) in May 2011. He has been involved in several major international and national research studies including the INTERHEART Study, the CREATE Trial, Indian Council of Medical Research commissioned national case-control study on Acute myocardial infarction, British Heart Foundation funded projects on low birth weight and migrant Gujaratis, Wellcome trust funded impact of intra-country migration on CHD, the NIH sponsored STICH trial and the India Health Study. In addition, he is involved with many community based prevention programs. He has recently been awarded the prestigious NHLBI-Ovations Grant and is a co-investigator for the Fogarty International-funded capacity building project. He is also Professor of Chronic Disease Epidemiology at the Public Health Foundation of India and Deputy Director of the South Asia center for Chronic Diseases Funded by the Wellcome Trust.

He is a member of various national and international organizations like Scientific Council of the Section on Epidemiology and Prevention of the World Heart Federation, Cardiological Society of India, Association of Physicians of India, Indian Council of Medical Research’s Project Review Committee on Cardiology and Indian Council of Medical Research’s Advisory Committee on Hypertension.   He is a member of several international bodies, is on the review board of national and international journals and is a reviewer for national and international research funding agencies such as the Wellcome Trust. He is also a referee for scientific paper assessments for the National Medical Journal of India, Indian Heart Journal, Journal of the National Academy of Medical Sciences, Indian Journal of Medical Research, and Hypertension and International Journal of Cardiology. He was an associate editor of JECH, which is a BMJ group journal until February 2011. He is a co-editor of Global Heart which is the official journal of the World Heart Federation. He has more than 150 publications in high impact prestigious journals including the, Lancet, BMJ, JAMA, New England Journal of Medicine and Proceedings of National Academy of Sciences, USA etc.


Harvey Rubin


Dr. Rubin is Professor of Medicine, University of Pennsylvania. He received his Ph.D. in Molecular Biology from the University of Pennsylvania in 1974 and his M.D. from Columbia University in 1976. He was a House Officer in Medicine at The Peter Bent Brigham Hospital in Boston and did his fellowship in infectious diseases at Harvard and the Brigham. He is currently Professor of Medicine at the University of Pennsylvania with secondary appointments in the Departments of Microbiology, Biochemistry and Computer and Information Sciences. His research on the basic biology of tuberculosis and the mathematical modeling of complex biological systems has been funded by the NIH, NSF, DARPA and the Global Alliance for TB Drug Discovery. He has published over 90 papers in peer reviewed journals as well as numerous scientific reviews and book chapters.

Dr. Rubin served on a number of national and international scientific review panels including those for the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the United States National Science Advisory Board for Biosecurity (NSABB) and the Department of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program. He is the Chair of the Scientific Advisory Board for the Incentives for Global Health.

Dr. Rubin is the Director of Penn’s Institute for Strategic Threat Analysis and Response (ISTAR). ISTAR is dedicated to identifying, analyzing and solving policy, scientific and technical issues that contribute to regional, national and international security.


Joshua Salomon


Joshua Salomon is Associate Professor of International Health in the Department of Global Health and Population at Harvard School of Public Health. His research focuses on priority-setting in global health, within three main substantive areas: 1) measurement and valuation of population health; 2) modeling of patterns and trends in major causes of global mortality and disease burden; and 3) evaluation of health policies and interventions. Prof. Salomon is an investigator on projects funded by NIH and the Gates Foundation relating to comparability of health measures; the global burden of disease; modeling of infectious and chronic diseases and interventions; and evaluating the potential impact and cost effectiveness of new health technologies. Prof. Salomon received his PhD in Health Policy and Decision Science from Harvard University.


Mel Spigelman

SpigelmanDr. Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance). Prior to being appointed President and CEO in 2009, Dr. Spigelman served for five and a half years as the Director of Research and Development at the TB Alliance. A highly regarded expert in domestic and international drug research and development, Dr. Spigelman previously spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma). As Vice President of R&D at Knoll for eight years, Dr. Spigelman directed clinical development and supervised all R&D activities from basic discovery to regulatory approval and Medical Affairs. He established global R&D processes as part of Knoll’s senior R&D management team, oversaw a marked increase in US regulatory filings and approvals, and supervised joint R&D programs with multiple other pharmaceutical companies.

Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine, Neoplastic Diseases and Preventive Medicine. Dr. Spigelman holds board certifications from the American Board of Internal Medicine, the American Board’s Subspecialty Board of Medical Oncology, and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988).

Presently, Dr. Spigelman serves on the Coordinating Board of the WHO Stop TB Partnership, is Co-chair of the Working Group on New Drugs of the WHO Stop TB Partnership, and is a member of the Governing Board of the Tres Cantos Open Lab, GlaxoSmithKline.


Sonali Kochhar

SpigelmanDr Kochhar, M.D., Clinical Research & Drug Development Specialist, PATH has extensive global experience in vaccines and drug development for infectious diseases (including HIV/AIDS). She has been responsible for providing leadership for clinical development strategy, design, implementation and medical oversight for international multi-centric, multi-country trials. She has provided clinical and regulatory support for Phase I – IV international trials for vaccines and drugs conducted in adult and pediatric populations in the USA, Europe, India, Africa and Asia. In her previous position as Medical Director for the International AIDS Vaccine Initiative, she provided leadership for the first AIDS vaccine trials in India.

She has also been responsible for scientific advocacy and partnership development with international and national government partners, public health authorities, regulatory bodies, pharmaceutical companies, local communities and the media. She works with government partners for national policy and program development, including for care and treatment guidelines for trial participants. She has also worked with vulnerable communities affected with HIV (including female sex workers, men who have sex with men, and transgender individuals).

Dr Kochhar received her M.D. in Pharmacology, has done international advanced vaccinology courses from the University of Geneva and Fondation Mérieux, Annecy, France (ADVAC) and Seoul, Korea (Advanced Course on Vaccinology in Asia-Pacific Region) and epidemiology from the London School of Hygiene and Tropical Medicine. She has served as guest faculty for international vaccinology and clinical research professional programs, is a member of international groups involved in the development of a WHO globally integrated vaccine safety monitoring system, safety standards for malaria, tuberculosis and AIDS vaccine trials, the Harvard University Multi-Regional Clinical Trial Steering Committee, the Global Health Clinical Consortium Leadership Group set up by the Gates Foundation and the Vienna Vaccine Safety Initiative working on global clinical research and safety. Kochhar serves on several international scientific advisory boards, has published numerous scientific papers, and has written book chapters on vaccine and drug development.


Management Team

Professor Thomas Pogge


Having received his Ph.D. in philosophy from Harvard University, Thomas Pogge writes and teaches on moral and political philosophy and Kant. His recent publications include John Rawls: His Life and Theory of Justice, Oxford 2007;Freedom from Poverty as a Human Right, edited, Oxford 2007; Global Institutions and Responsibilities, edited with Christian Barry, Blackwell 2005; Real World Justice, edited with Andreas Follesdal, Springer 2005; World Poverty and Human Rights, Polity 2002; and Global Justice, edited, Blackwell 2001. Pogge is editor for social and political philosophy for theStanford Encyclopedia of Philosophy and a member of the Norwegian Academy of Science.

His work was supported, most recently, by the John D. and Catherine T. MacArthur Foundation, the Princeton Institute for Advanced Study, All Souls College (Oxford), the National Institutes of Health (Bethesda), the Australian Research Council, and the BUPA Foundation.

He is currently Leitner Professor of Philosophy and International Affairs at Yale University, Professorial Fellow at the ANU Centre for Applied Philosophy and Public Ethics (CAPPE), and Research Director at the Oslo University Centre for the Study of Mind in Nature (CSMN).


Professor Aidan Hollis

hollisAidan Hollis is a Professor of Economics at the University of Calgary. He was educated at Cambridge University (BA) and the University of Toronto (MA, PhD). His research focuses on pharmaceutical markets — including issues relating to innovation, competition, trade, and access. He has also published more broadly in economics within the field of industrial organization, including on a historical Irish microfinance institution. Hollis worked in corporate banking for several years in London and Seoul, and in 2003-4 served as the T.D.MacDonald Chair of Industrial Economics at the Competition Bureau, Ottawa.  More information is available at his university webpage:


Tim Gilbert

GilbertTim Gilbert is a partner and founder of Gilbert’s LLP. He was called to the Ontario Bar in 1990 and founded Gilbert’s in 2001 after spending eight years with a prominent Toronto boutique litigation firm where he was a partner. He is an able and experienced trial advocate and has represented clients in various courts and forums in a variety of areas. He is known and respected in the commercial courts of Ontario and the Federal Court of Canada and has broad experience in intellectual property litigation in several leading industries, including the pharmaceutical, high-tech and financial services industries.

Gilbert has significant experience in pharmaceutical regulatory law and competition law effectively representing clients concerning all aspects of the manufacture and sale of pharmaceutical products in both Canada and the United States. He also has a diverse government relations practice in Canada and in the United States. He teaches trial advocacy at the Faculty of Law at University of Toronto, Osgoode Hall Law School, the Advocates’ Society and the Food and Drug Law Institute.

Gilbert founded Gilbert’s Global, which provides strategic consulting and legal services to companies, civil society organizations, governments and international agencies that are grappling with issues related to global health, trade, technology, sustainability and intellectual property.

Dave Goodsmith

GoodmanDave Goodsmith is the Chief Financial Officer of Incentives for Global Health, as well as the Secretary of the Board. Dave is the co-founder and co-chair of NYC Results, a policy advocacy group with a focus on U.S. foreign aid. He has managed research in cognitive neuroscience at Columbia University’s Center for the Decision Sciences and worked as a research analyst at D.E. Shaw & Co. Prior to his career in research, Dave spent over ten years as a management consultant to leading multi-national corporations, guiding executives on technology infrastructure and knowledge management strategies. Dave is interested in the neural foundations for ethical behavior and novel approaches to behavioral economics. He has a degree in Environmental Science and Public Policy from Harvard University.

Amitava Banerjee

GoodmanAfter studying at Oxford Medical School, Ami trained as a junior doctor in Oxford, Newcastle, Hull and London, and is now Clinical Lecturer in Cardiovascular Medicine at the University of Birmingham. Epidemiology and evidence-based medicine were the obvious ways to marry his passions for cardiology and public health, leading to a Masters in Public Health from Harvard University and a DPhil in cardiovascular epidemiology from Oxford University. He first worked with the Cardiovascular Diseases Division at the World Health Organization as an intern in 2005, but has continued to work there as a Temporary Advisor. Ami spends his time between cardiology, research and teaching. Outside of clinical practice, his interests include global health, improving access to medicines and public understanding of medical research. Ami also co-writes a popular evidence-based medicine blog, He is medical advisor to Incentives for Global Health.


Jake Hirsch-Allen

hirsch-allenJake Hirsch-Allen is a lawyer with a background in foreign policy, international criminal and intellectual property law. Jake recently articled at Gilbert’s LLP, an intellectual property litigation boutique in Toronto, and clerked for the Supreme Court of Israel. In addition to acting as the Executive Director of McGill’s International Criminal Law Clinic, Jake has worked for the Department of Foreign Affairs Canada, McGill’s Centre for Intellectual Property Policy and UofT’s Munk Center for International Studies. He has interned at Human Rights Watch and on Radovan Karadzic and Ieng Thirith’s defense teams at the International Criminal Tribunal for the former Yugoslavia (ICTY) and the Extraordinary Chambers in the Courts of Cambodia (ECCC) respectively. Jake has conducted research for Professors Margaret MacMillan, Payam Akhavan, Frederic Megret, Paul Litt, Sylvia Ostry and Goran Sluiter, among others. Jake has a Bachelor of Civil Law and a Bachelor of Common Law from McGill University’s Faculty of Law (2010). He received his B.A. in International Relations and Archetypal Mythology from the University of Toronto (UofT) in 2005.


Narmeen Haider


Narmeen Haider is a manager for the Health Impact Fund and a instructor at McMaster University in the Department of Health Sciences. She holds an MSc in International Health Policy from the London School of Economics and Political Science and a BHSc from McMaster University. Previously, Narmeen has worked for Johnson & Johnson’s government affairs and policy department in the United Kingdom.


Zain Rizvi


Zain Rizvi is a research analyst for the Health Impact Fund. In his final year of the Bachelor of Health Sciences program at McMaster University, Zain also serves as a Fellow at the McMaster Health Forum. In addition, he coordinates the child sponsorship program for True Vision Ghana, a grassroots Ghanaian NGO that works with children affected by HIV/AIDS.


Nathaniel Lipkus

segersonNathaniel Lipkus is a partner at Gilbert’s LLP in Toronto. Nathaniel’s practice includes intellectual property litigation and government relations, focusing primarily within the pharmaceutical and high-tech industries. He has advised pharmaceutical industry clients on patent issues, as well as regulatory approval challenges, pricing and reimbursement, anti-counterfeiting enforcement, and regulatory pathways for biological drugs.

Nathaniel is a registered patent and trade-mark agent and holds Bachelor of Commerce, JD and MBA degrees from the University of Toronto. Nathaniel is Chair of the IP Trade Policy Committee at the Intellectual Property Institute of Canada. He also sits on the American Bar Association’s Patent Litigation Committee and is a peer reviewer for the Canadian Intellectual Property Review. Nathaniel has written recent peer-reviewed articles on public-private partnerships for drug development, the interplay between collaboration and IP secrecy, and the proper scope of patentable arts.